Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas

Completed · Phase 1/Phase 2

Conditions studied: Leukemia, Lymphocytic, Lymphoma

In brief

The purpose of this study is to determine if intravenous BCX-1777 can be given safely to improve relapsed or refractory aggressive T-cell leukemias and lymphomas.

Key facts

Study ID
NCT00035022
Run by
BioCryst Pharmaceuticals
People needed
71
Starts
2001-08-01
Expected to finish
2004-03-01
Last updated by the study team
2006-01-13

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.